These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

845 related items for PubMed ID: 17571068

  • 1. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC, Cross JT.
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disease models.
    Gobburu J.
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
    [No Abstract] [Full Text] [Related]

  • 4. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB, Obach RS.
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK.
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN, Horvath CJ.
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
    Sinha V, Zhao P, Huang SM, Zineh I.
    Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
    de Leon J, Spina E, Diaz FJ.
    J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacogenomics. Going from genome to pill.
    Service RF.
    Science; 2005 Jun 24; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract] [Full Text] [Related]

  • 13. Using disease progression models as a tool to detect drug effect.
    Mould DR, Denman NG, Duffull S.
    Clin Pharmacol Ther; 2007 Jul 24; 82(1):81-6. PubMed ID: 17507925
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Initial human trials with an investigational new drug (phase I and 2): planning an management.
    Vaidya AB, Vaidya RA.
    J Postgrad Med; 1981 Oct 24; 27(4):197-213. PubMed ID: 7338825
    [No Abstract] [Full Text] [Related]

  • 16. Historical development of pediatric pharmacology.
    Seyberth HW, Rane A, Schwab M.
    Handb Exp Pharmacol; 2011 Oct 24; 205():v-vi. PubMed ID: 22046631
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dying to live.
    Nat Med; 2006 Jun 24; 12(6):593. PubMed ID: 16760985
    [No Abstract] [Full Text] [Related]

  • 19. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA.
    Food Drug Law J; 2003 Jun 24; 58(1):103-27. PubMed ID: 12739592
    [No Abstract] [Full Text] [Related]

  • 20. Overhauling clinical trials.
    Scott CT, Baker M.
    Nat Biotechnol; 2007 Mar 24; 25(3):287-92. PubMed ID: 17344876
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.